ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression, according to a study published  in the open-acess journal PLOS ONE.

Cancer stem cells survive after chemotherapy and radiation treatment and are associated with recurrence, metastasis and poor survival in clinical trials.

Previous studies have shown that a small molecule known as ONC201 currently in advanced cancer clinical trials, targets self-renewing colorectal cancer stem cells.

However, little is known about the specific stem cell-related effects by which ONC201 inhibits cancer stem cells from renewing.

Varun Vijay Prabhu and colleagues conducted a gene expression analysis of colorectal, prostate cancer and glioblastoma cell lines and patient-derived tissues that were both treated with ONC201.

They found that ONC201 alters the gene expression of cancer stem cell markers and signalling pathways prior to killing the tumour cells, providing pharmacodynamic biomarkers of response.

These changes were not observed in cells with acquired resistance to ONC201.

Finally, the authors suggest that a pre-treatment gene expression signature of cancer stem cells might be able to help predict the response to ONC201.

These findings provide further evidence of ONC201 as an inhibitor of cancer stem cells and support ongoing clinical trials in prostate cancer and glioblastoma that have shown evidence of tumour shrinkage.

Further research could test these cancer stem cell gene expression at the RNA and protein level in circulating tumour cells and biopsies from patients on trial.

Source:  PLOS